Vanderbilt University Medical Center: Study Sheds Light on Drug's Impact on Diabetes Progression
March 24, 2023
March 24, 2023
NASHVILLE, Tennessee, March 24 (TNSjou) -- Vanderbilt University Medical Center issued the following news:
A 10-year study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.
A 10-year study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.